Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. L. Dente, F. Novelli, M. L. Bartoli, M. Carli, S. Cianchetti, A. Di Franco, E. Bacci, P. L. Paggiaro (Pisa, Italy). Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline. Eur Respir J 2011; 38: Suppl. 55, 909

Member's Comments

No comment yet.

Related content which might interest you: Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Regular follow-up visits reduce the risk for severe asthma exacerbation required admission Source: International Congress 2017 – Chronic airway disease: markers of disease impact Year: 2017 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 R411 treatment reduces asthma exacerbations and attenuates FEV1 fall following steroid withdrawal in moderate asthma Source: Eur Respir J 2005; 26: Suppl. 49, 252s Year: 2005 FEV1 decline in occupational asthma Source: Eur Respir J 2003; 22: Suppl. 45, 488s Year: 2003 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018 Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005 Change in clinical COPD questionnaire (CCQ) symptoms domain score and FEV1 predict treatment failure during hospitalisation due to COPD exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003 Severe exacerbations predict excess lung function decline in asthma Source: Eur Respir J 2007; 30: 452-456 Year: 2007 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 FEV1 decline and eosinophilia in occupational asthma Source: Annual Congress 2011 - The work environment in the clinic Year: 2011 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016